MedTrace Logo

Diagnostic Accuracy of Placental Thickness in Lower Uterine Segment Measured By Ultrasound in Prediction of Placenta Accreta Spectrum in Patients With Placenta Previa. A Diagnostic Test Accuracy Study

NCT05500404 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-11-23

No results posted yet for this study

Summary

Current prenatal diagnosis of placenta accrete spectrum disorders relies on subjective individual interpretations of visual sonographic findings on grayscale and color Doppler imaging. When blinded to clinical data, there is significant interobserver variability in the diagnosis of invasive placentation.

This study will evaluate placental thickness among pregnant women with placenta previa and determine if increased placenta thickness correlates with the risk for placenta accreta spectrum (PAS) disorders.

Conditions

  • Placenta Accreta Spectrum

Interventions

DIAGNOSTIC_TEST

Ultrasound measurment of placental thickness

The maximum placental thickness in the lower uterine segment will obtained using trans-abdominal ultrasound scan. For the image to be deemed suitable, a midline sagittal section of the lower uterine segment (with the implanted placenta) and the cervical canal, with the intervening urinary bladder will be required (Bhide et al., 2019). The measurement will be performed by a researcher who will be blinded to the final diagnosis.

Sponsors & Collaborators

  • Ain Shams Maternity Hospital

    lead OTHER

Principal Investigators

  • Ahmed M Mamdouh, MD · Ainshams university maternity hospital

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05500404 on ClinicalTrials.gov